Acthar Gel Eases MS Flare-up Symptoms After Two Months of Treatment, Observational Study Shows

Acthar Gel Eases MS Flare-up Symptoms After Two Months of Treatment, Observational Study Shows

Publication date: Oct 03, 2019

Acthar Gel (repository corticotropin injection) eased flare-up symptoms in patients with multiple sclerosis (MS) experiencing relapses, top-line data from an observational registry study shows. The main goal of the study was to monitor the course of MS, document all relapses and the recovery process in a group of MS patients who had been treated with Acthar Gel for at least six months. The primary goal of the study was to assess the effect of Acthar Gel on symptoms associated with MS flare-ups after two months of treatment, based on the MSIS-29v1 scale (a tool that measures the impact of MS in physical and psychological aspects from a patient’s perspective). Top-line data from the study showed that patients treated with Acthar Gel not only reported marked improvements in their symptoms after two months of therapy, but also had a sustained response to the medication that was still apparent six months after enrolling in the study.

Concepts Keywords
Acthar MS
Clinical Trials Multiple sclerosis
Corticosteroids Mallinckrodt
Corticotropin
Double Blind
FDA
Flare
Mallinckrodt
Mallinckrodt Pharmaceuticals
Multiple Sclerosis
Placebo
Relapse
Steroids

Semantics

Type Source Name
drug DRUGBANK Corticotropin
disease MESH multiple sclerosis
disease DOID multiple sclerosis
disease MESH relapses
gene UNIPROT HMBS
gene UNIPROT IMPACT
pathway BSID Release
disease DOID relapsing-remitting MS

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *